Expression patterns and clinical implications of chaperonin subunit 3 mRNA and protein in laryngeal squamous cell carcinoma

Figure 1 Chaperonin-containing TCP1 subunit 3 mRNA levels in laryngeal squamous cell carcinoma are consistently higher compared to non-cancerous tissue. NS: Not significant.

Figure 2 Chaperonin-containing TCP1 subunit 3 mRNA has a marvelous performance in discriminating between laryngeal squamous cell carcinoma and non-cancerous tissue. AUC: Area under the curve.

Figure 3 Chaperonin-containing TCP1 subunit 3 mRNA was significantly increased and has a strong discriminatory performance between laryngeal squamous cell carcinoma and non-cancerous tissue. A: The expression level of chaperonin-containing TCP1 subunit 3 mRNA in the Laryngeal squamous cell carcinoma group was significantly higher than that in the control group overall (the standardized mean difference = 1.32, 95% confidence interval: 0.79-1.84), but there was significant heterogeneity among the studies (I² = 75%); B: The summary receiver operating characteristic curve indicates that the discriminative performance of chaperonin-containing TCP1 subunit 3 mRNA is strong (area under the curve = 0.93), with sensitivity and specificity of 0.84 and 0.91, respectively. SMD: Standardized mean difference; CI: Confidence interval; SROC: Summary receiver operating characteristic; SENS: Sensitivity; SPEC: Specificity; AUC: Area under the curve.

Figure 4 Chaperonin-containing TCP1 subunit 3 mRNA has a strong discriminatory performance in laryngeal squamous cell carcinoma. A: The positive diagnostic likelihood ratio is 9.48, and the negative diagnostic likelihood ratio is 0.18; B: The overall sensitivity of the test is 0.84, and the specificity is 0.91.

Figure 5 Single cell expression analysis of chaperonin-containing TCP1 subunit 3 in laryngeal squamous cell carcinoma. These plots illustrate the expression patterns of Chaperonin-containing TCP1 subunit 3 and laryngeal squamous cell carcinoma-related marker genes, as well as the distribution and clustering of different cell types. tSNE: T-distributed stochastic neighbor embedding.

Figure 6 Immunohistochemical verification of chaperonin-containing TCP1 subunit 3 protein in laryngeal squamous cell carcinoma tissue. A and B: Chaperonin-containing TCP1 subunit 3 (CCT3) protein show negative intensity in non-cancerous squamous epithelium; C and D: CCT3 protein show positive intensity in the cytoplasm of laryngeal squamous cell carcinoma cell; E: The expression of CCT3 protein is significantly higher in laryngeal squamous cell carcinoma than in non-cancerous squamous epithelium; F: CCT3 protein has perfect diagnostic performance, accurately distinguishing between laryngeal squamous cell carcinoma and non-cancerous squamous epithelium. CCT3: Chaperonin-containing TCP1 subunit 3; LSCC: Laryngeal squamous cell carcinoma; AUC: Area under the curve.

Figure 7 Clustered regularly interspaced short palindromic repeats screen is used to identify the function of chaperonin-containing TCP1 subunit 3 by knocking them out and observing the effect on laryngeal squamous cell carcinoma. Laryngeal squamous cell carcinoma cell lines show a highly negative effect score, indicating that chaperonin-containing TCP1 subunit 3 knocking out may induce strongly inhibitory effect on laryngeal squamous cell carcinoma.

Figure 8 Gene set enrichment analysis of chaperonin-containing TCP1 subunit 3 in laryngeal squamous cell carcinoma. This gene set enrichment analysis plot for chaperonin-containing TCP1 subunit 3 provides a visual representation of which biological pathways are significantly enriched in the activated or suppressed conditions, helping to understand the functional impact of chaperonin-containing TCP1 subunit 3 on cellular processes.

Figure 9 Analysis of chaperonin-containing TCP1 subunit 3 protein interaction network. A: Kyoto Encyclopedia of Genes and Genomes (KEGG) cell cycle; B: KEGG DNA replication; C: KEGG Wnt signaling pathway.